Autoimmune Innovation at a Turning Point
Pipelines are expanding rapidly, with over 6,600 drugs now tracked in Beacon Autoimmune – a 27% year-on-year increase – and more than 1,100 new trials launched in the first six months of 2025. Innovation is accelerating as next-generation modalities, such as bispecific antibodies, and novel targets including TL1A and NLRP3, gain traction. Despite broader market uncertainty, commercial strength remains evident, with steady IPO activity and billion-dollar deals such as Vor Bio’s $4.1B licensing agreement. With 1,186 trials due to conclude by the end of 2025, the autoimmune field is on the brink of transformation – now is the moment to get ahead of the data that will soon redefine treatment pathways.
Report Contents
Spotlight on Multiple Sclerosis
This special feature provides in-depth, data-driven insights to support translational strategies, inform clinical development, and contextualize emerging mechanisms of action for research evaluation.
The Drug Landscape
Explore the drug landscape analysis, spotlight high-potential assets, and uncover where the next big breakthroughs may come from.
The Trial Landscape
Deep dive into the trial landscape and understand trial trends, status changes, and reasons for trial terminations.
The Commercial Landscape
A review of the top autoimmune deals so far in 2025, and a company landscape and founded analysis.
The Future of the Autoimmune Space
A glimpse into the future trajectory of the autoimmune market, with a focus on potential approvals and upcoming milestones.
Regulatory Announcements
A review of regulatory announcements, including IND/CTA filings and popular updates by drug type.
Previous Immune Tolerance Landscape Reviews
Immune Tolerance 2024 H1 Landscape Review
An analysis of the Immune Tolerance landscape in H1 of 2024
Immune Tolerance 2024 Landscape Review
An analysis of the Immune Tolerance landscape in 2024
You May Also Be Interested In…
Learn More About Autoimmune
- The Most Comprehensive Way to Search the Autoimmune Drug Development Landscape: Unique search ontologies based on Autoimmune drug and trial characteristics
- Market Leading Approach to Autoimmune Preclinical & Clinical Data Curation: Manual curation of key Autoimmune research and development data points by Autoimmune research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Autoimmune company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
